Research shows potential new way to treat brain cancer

December 7, 2018, Victoria University of Wellington
Credit: Victoria University of Wellington

Research conducted at Victoria University of Wellington and the Malaghan Institute of Medical Research has suggested a potential new way of treating glioblastoma, an aggressive form of brain cancer.

Nicole Jones, who graduates next week with her Ph.D., played a significant role in the work, which was led by Dr. Melanie McConnell of the University's School of Biological Sciences.

Nicole's suggests that suppressing a gene called BCL6 could help treat . Past research has shown BCL6 plays a significant role in many cancers, suppressing and preventing them from growing, but newer research suggested BCL6 might play a different role in glioblastoma, Nicole says. Her Ph.D. research aimed to investigate what role BCL6 played in glioblastoma.

"Throughout my Ph.D. I completed extensive tests on the role of BCL6 in glioblastoma," Nicole says. "My results seem to show that BCL6 has the opposite effect in glioblastoma than in other cancers. In glioblastoma, BCL6 seems to activate cells and encourage them to grow. It also seems to connect to a very different part of the genome in glioblastoma than in other cancers."

If BCL6 is responsible for activating glioblastoma cancer cells, suppressing the function of BCL6 could provide a possible new avenue for treating this cancer, Nicole says.

"The measured the effect that current BCL6-suppressing drugs have on glioblastoma cells, and the results were promising," Nicole says. "These drugs, in combination with chemotherapy, do seem to kill off glioblastoma cells. If further tests support these results this would be an amazing leap forward for this field, because there has been very little change in treatment for people diagnosed with this terrible disease in the past 30 years."

Dr. McConnell's research group will continue work in this area, confirming Nicole's findings and looking at why BCL6 seems to have this effect on glioblastoma and how this effect might lead to new treatments.

Nicole's goal was always to attend Victoria University of Wellington and study at the Malaghan Institute of Medical Research to help create cancer therapies. She first worked with Dr. McConnell in her honours year before going on to Ph.D. study.

"I always wanted to pursue cancer research, as I have had multiple family members affected by cancer," Nicole says. "During my honours study I began work on glioblastoma, and luckily all the funding stars aligned and I could continue this project during my Ph.D. I hope to continue work on new cancer therapies throughout my career."

Explore further: Researchers identify potential target for treatment of aggressive brain cancer

More information: The thesis is available online: researcharchive.vuw.ac.nz/handle/10063/7682

Related Stories

Researchers identify potential target for treatment of aggressive brain cancer

June 7, 2017
Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore have discovered that the BCL6 protein could potentially be used as a marker to predict clinical outcomes of ...

Research team identifies a potential strategy in fight against brain cancer

September 11, 2018
Scientists with the Virginia Tech Carilion Research Institute say a gene involved in the body's circadian rhythms is a potential target for therapies to help patients with a deadly form of brain cancer known as glioblastoma.

Identification of PTPRZ as a drug target for cancer stem cells in glioblastoma

July 19, 2017
Glioblastoma is a malignant brain tumor with high mortality. Cancer stem cells are thought to be crucial for tumor initiation and its recurrence after standard therapy with radiation and temozolomide (TMZ) chemotherapy. Protein ...

A maestro that conducts the invasiveness of glioblastoma tumors

June 14, 2018
Glioblastoma is the most severe form of brain cancer in adults. The aggressiveness of this cancer is largely due to its ability to invade surrounding brain tissue, making the tumor difficult to remove by surgery. Now, a research ...

Using a microRNA to shift the makeup of glioblastoma subtypes

July 13, 2017
Glioblastoma multiforme (GBM), an extremely aggressive brain cancer, is a very complex disease. It is characterized by a fast-growing tumor in the brain composed of many subpopulations of cells, including glioblastoma stem ...

Insights into how brain cancer evades the immune system

March 7, 2018
Glioblastoma—a universally fatal form of brain cancer—is known for its ability to hijack immune checkpoints and evade detection and destruction by the body's immune defenses. But many of the details underlying this feat ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.